摘要
目的探究奥沙利铂联合卡培他滨治疗晚期结肠癌的效果和安全性。方法选取我院2016年1月至2016年12月期间收治的36例晚期结肠癌患者作为研究对象。将所有患者随机均分成研究组、对照组,各18例。给予对照组患者单纯奥沙利铂治疗,给予研究组患者奥沙利铂联合卡培他滨治疗。观察、对比两组患者的治疗效果、不良反应发生情况、随访2年的生存时间及血清指标水平等。结果研究组患者治疗总有效率77.78%高于对照组患者的50.0%,P<0.05,差异有统计学意义。研究组、对照组患者总不良反应发生率均为50.0%,二者相比并无差异,P>0.05,差异无统计学意义。研究组患者生存时间为(11.7±3.7)个月长于对照组患者生存时间(7.5±1.9)个月,P<0.05,差异有统计学意义。研究组患者1年生存率61.11%、2年生存率27.78%均高于对照组的50.0%、11.11%,P<0.05,差异有统计学意义。两组患者治疗后DOC2蛋白水平均高于治疗前,且研究组高于对照组;两组患者治疗后rasP21蛋白、c-Fos蛋白、IL-6水平均低于治疗前,且研究组低于对照组,P<0.05,差异有统计学意义。结论给予晚期结肠癌患者奥沙利铂联合卡培他滨治疗可有效提高患者疗效,降低血清相关指标水平及不良反应发生率,安全性高,利于延长患者生命,值得临床大力推广及应用。
Objectives To investigate the efficacy and safety of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer.Methods Thirty-six patients with advanced colon cancer admitted to our hospital from January 2016 to December 2016 were selected as subjects.All patients were randomly divided into study group and control group,with 18 cases in each group.Patients in the control group were treated with oxaliplatin alone,and the patients in the study group were treated with oxaliplatin plus capecitabine.The therapeutic effects,the incidence of toxic and side effects,the survival time of 2 years of follow-up,and the serum index levels were observed and compared between the two groups.Results The total effective rate of the study group was 77.78%higher than that of the control group,which was 50.0%,P<0.05,and the difference was statistically significant.The incidence of total toxic and side effects in the study group and the control group were 50.0%,there was no difference between the two groups,P>0.05,the difference was not statistically significant.The survival time of the study group was(11.7±3.7)months longer than that of the control group(7.5±1.9)months,P<0.05,the difference was statistically significant.The 1-year survival rate of the study group was 61.11%,and the 2-year survival rate was 27.78%,which was higher than that of the control group(50.0%,11.11%,P<0.05).The difference was statistically significant.The levels of DOC2 protein in the two groups were higher than those before treatment,and the study group was higher than the control group.The rasP21 protein,c-Fos protein and IL-6 levels in the two groups were lower than those before treatment,and the study group was lower than the treatment group.In the control group,P<0.05,the difference was statistically significant.Conclusion Administration of oxaliplatin combined with capecitabine in patients with advanced colon cancer can effectively improve the efficacy of patients,reduce the level of serum-related indicators and the incidence of t
作者
张红娟
于振东
张红波
吕巧妹
张艳平
ZHANG Hong-juan;YU Zhen-dong;ZHANG Hong-bo;LV Qiao-mei;ZHANG Yan-ping(Dandong Central Hospital,Dandong 118000,China;Second Hospital of Jilin University,Changchun 130000,China)
出处
《中国医药指南》
2020年第12期87-88,共2页
Guide of China Medicine
